 Palisade Bio Inc NASDAQ: PALI has received a Study May Proceed letter from the FDA for a Phase 3 trial to evaluate LB1148 to accelerate the return of bowel function in adult patients undergoing bowelabdominal surgery. The trial will enroll approximately 600 subjects. 